Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Neoplasm Metastasis 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × merestinib × Clear all
NCT02711553 2025-08-03

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Eli Lilly and Company

Phase 2 Active not recruiting
309 enrolled 22 charts
Gastrointestinal

Biliary Tract Neoplasms, Neoplasm Metastasis

NCT02920996 2024-04-11

Merestinib In Non-Small Cell Lung Cancer And Solid Tumors

Dana-Farber Cancer Institute

Phase 2 Terminated
12 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡